Stock Events

Moderna 

$61.92
2012
-$1.24-1.96% Today

Statistics

Day High
62.91
Day Low
61.55
52W High
170.47
52W Low
61.55
Volume
2,408,261
Avg. Volume
4,620,431
Mkt Cap
29.75B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-9.53
-6.17
-2.81
0.55
Expected EPS
-1.636491
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MRNA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a direct competitor in the COVID-19 vaccine market, with its mRNA vaccine developed in collaboration with BioNTech.
BioNTech
BNTX
Mkt Cap20.98B
BioNTech SE partnered with Pfizer to develop a COVID-19 mRNA vaccine, competing directly with Moderna's mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson competes in the COVID-19 vaccine space with its viral vector vaccine, offering an alternative to mRNA vaccines.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca competes with Moderna with its COVID-19 vaccine developed in collaboration with Oxford University, using a different technology (viral vector).
Novavax
NVAX
Mkt Cap1.98B
Novavax offers a protein subunit COVID-19 vaccine, providing an alternative to Moderna's mRNA vaccine.
Sanofi
SNY
Mkt Cap141.43B
Sanofi, through its partnership with GlaxoSmithKline, is developing COVID-19 vaccines that compete with Moderna's offerings.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline, in collaboration with Sanofi, is working on COVID-19 vaccines, positioning it as a competitor to Moderna.
CureVac N.V.
CVAC
Mkt Cap704.35M
CureVac competes in the mRNA space, focusing on developing mRNA-based vaccines and therapeutics, including for COVID-19.
Merck
MRK
Mkt Cap300.25B
Merck is involved in the development of COVID-19 treatments and vaccines, making it a competitor in the broader infectious disease market.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories competes with Moderna in the broader healthcare sector, including diagnostics and medical devices for infectious diseases.

Analyst Ratings

101.5$Average Price Target
The highest estimate is $151.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
29%
Hold
64%
Sell
7%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Stephane Bancel
Employees
5600
Country
US
ISIN
US60770K1079

Listings